v3.26.1
Summary of Significant Accounting Policies - Additional Information (Detail)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
USD ($)
$ / shares
Mar. 31, 2026
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Jun. 30, 2026
USD ($)
Segment
$ / shares
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Summary Of Significant Accounting Policies [Line Items]              
Cash, cash equivalents and restricted cash, maturity period         three months or less    
Net loss $ (31,630) $ (39,025) $ (11,216) $ (6,495) $ (70,655) $ (17,711)  
Cash and cash equivalents and short-term investments 88,800       88,800    
Working capital 81,300       81,300    
Accumulated deficit (471,858)       $ (471,858)   $ (401,203)
Going concern conditions or events description         Based on the Company's current operating plan, the Company expects that, within the next twelve months, its existing cash, cash equivalents, short-term investments and other available resources will not be sufficient to fund its planned operations and satisfy its obligations as they become due unless it obtains additional financing. Based on these conditions and events that are known and reasonably knowable as of the date these condensed consolidated financial statements are issued, management has concluded that substantial doubt exists about the Company's ability to continue as a going concern.    
Recognized expense of employer contributions to the plan $ 100   $ 100   $ 300 $ 200  
Convertible preferred stock, par value | $ / shares $ 0.001       $ 0.001    
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]         srt:ChiefExecutiveOfficerMember    
Segment Reporting, Factors Used to Identify Entity's Reportable Segments         The CODM manages and allocates resources to the operations of the Company on a total company basis. Managing and allocating resources on a consolidated basis enables the CODM to assess the overall level of resources available and how to best deploy these resources across functions, therapeutic areas and research and development projects that are in line with the Company’s long-term company wide strategic goals.    
Number of operating segments | Segment         1    
Number of reportable segments | Segment         1    
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description         the CODM uses consolidated net income (loss) for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. Operating expenses are used to monitor budget versus actual results.    
Employee Stock Option | Board of Directors [Member]              
Summary Of Significant Accounting Policies [Line Items]              
Expected life assumption using simplified method, description         For stock options granted to the Company’s board of directors (the “Board”), the Company determined the expected life assumption using the simplified method as the starting point with an average period of 12 months added to take into account the extended range of time of 12 to 18 months that vested stock options granted to Board members may be exercised upon termination.    
Maximum [Member] | Employee Stock Option | Board of Directors [Member]              
Summary Of Significant Accounting Policies [Line Items]              
Vesting period of stock options granted         18 months    
Minimum [Member] | Employee Stock Option | Board of Directors [Member]              
Summary Of Significant Accounting Policies [Line Items]              
Vesting period of stock options granted         12 months    
Series X and Series X1 Non-voting Convertible Preferred Stock [Member]              
Summary Of Significant Accounting Policies [Line Items]              
Convertible preferred stock, par value | $ / shares $ 0.001       $ 0.001    
Anelixis Therapeutics, LLC and Otic Pharma, Ltd.              
Summary Of Significant Accounting Policies [Line Items]              
Ownership interest percentage         100.00%    
Otic Pharma, Inc. [Member]              
Summary Of Significant Accounting Policies [Line Items]              
Ownership interest percentage         100.00%